<code id='9B7CC5158C'></code><style id='9B7CC5158C'></style>
    • <acronym id='9B7CC5158C'></acronym>
      <center id='9B7CC5158C'><center id='9B7CC5158C'><tfoot id='9B7CC5158C'></tfoot></center><abbr id='9B7CC5158C'><dir id='9B7CC5158C'><tfoot id='9B7CC5158C'></tfoot><noframes id='9B7CC5158C'>

    • <optgroup id='9B7CC5158C'><strike id='9B7CC5158C'><sup id='9B7CC5158C'></sup></strike><code id='9B7CC5158C'></code></optgroup>
        1. <b id='9B7CC5158C'><label id='9B7CC5158C'><select id='9B7CC5158C'><dt id='9B7CC5158C'><span id='9B7CC5158C'></span></dt></select></label></b><u id='9B7CC5158C'></u>
          <i id='9B7CC5158C'><strike id='9B7CC5158C'><tt id='9B7CC5158C'><pre id='9B7CC5158C'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:93
          Cigna Healthcare's logo on a phone
          Adobe

          CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to the health care conglomerate anytime soon.

          A federal appeals court has ruled Bricker, a former high-ranking executive at Cigna, cannot jump to CVS because it would violate her noncompete agreement that she signed while at Cigna. The appeals court’s decision backs up what a district court had previously ruled.

          advertisement

          The case is a prominent example of why the health care industry, and corporate America writ large, does not want noncompetes to go away. In April, the Federal Trade Commission approved a nationwide ban on most such agreements, which prevent workers from moving to other jobs, but companies and corporate lobbying groups have already sued to squash the ban.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          FDA approves potent Eli Lilly obesity drug, Zepbound
          FDA approves potent Eli Lilly obesity drug, Zepbound

          DarronCummings/APEliLilly’sblockbusterdrugtirzepatide,soldasMounjarofortype2diabetes,hasbeenclearedt

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          FDA approves Recor Medical high blood pressure device

          ReCorMedical,astartupownedbyJapanesecompanyOtsukaMedicalDevices,andMedtronichaverunstudiesthatshowed